Jonathan Y An, Kristopher A Kerns ... Matt Kaeberlein
Short-term treatment with rapamycin reverses periodontal bone loss, attenuates inflammation, and remodels the oral microbiome toward a more youthful state.
Alessandro Bitto, Takashi K Ito ... Matt Kaeberlein
Three months treatment with the drug rapamycin increases lifespan, alters cancer prevalence, remodels the microbiome, and improves functional measures of health in middle aged mice in a dose- and sex-dependent manner.
A novel genome-wide transcriptional activation screening in Drosophila cells revealed the activation of InR-Akt-mTOR pathway by cholesterol in plasma membrane to confer resistance to Rapamycin.
Rapamycin treatment inhibits mTOR activity and preserves ATP levels in neurons derived from induced pluripotent stem cells from a maternally inherited Leigh syndrome patient.
Stella Reichling, Peter F Doubleday ... Duncan Holbrook-Smith
High throughput metabolome profiling of yeast cells that are dynamically perturbed with the drug rapamycin can be used to implicate new genes in the key cellular process of TOR signaling, including the gene of unknown function CFF1.
Margaret E Torrence, Michael R MacArthur ... Brendan D Manning
ATF4 is a metabolic effector of mTORC1 signaling, co-opted to induce gene targets involved in amino acid synthesis, uptake, and tRNA charging, contributing to mTORC1-driven protein and glutathione synthesis.
M Regina Scarpin, Samuel Leiboff, Jacob O Brunkard
Plants and humans use a shared mechanism, the eukaryotic metabolic sensor TARGET OF RAPAMYCIN protein kinase and its substrate, an RNA-binding protein called LARP1, to coordinate post-transcriptional gene expression.
Modulation of histone levels in gut enterocytes by rapamycin treatment alters chromatin organisation and induces intestinal autophagy through transcriptional regulation to prevent age-related decline in the intestine and extend lifespan.
The cyclic-peptide antibiotic GE23077 inhibits bacterial RNA polymerase through a novel target that exhibits low susceptibility to target-based resistance and that enables synthesis of bipartite inhibitors that are exceptionally potent and refractory to target-based resistance.